What can I take instead of Mounjaro for weight loss?

Step 1: Get clear on why Mounjaro may not be suitable for you

Before reaching for an alternative, it helps to know which part of the picture rules Mounjaro out. Sometimes it is clinical: a history of pancreatitis, medullary thyroid carcinoma, or certain gastrointestinal conditions can mean tirzepatide is not appropriate. Sometimes it is practical: Mounjaro requires refrigerated storage, which can be difficult when travelling or if your home situation makes that awkward. And sometimes it is simply that you have already tried it and the side effects or the response weren't what you needed.

A quick thing worth doing before your consultation: note down any medicines you take regularly, including the contraceptive pill. Women on oral contraceptives need to use an additional non-oral method of contraception for the first four weeks of Mounjaro and for four weeks after each dose increase, because gut-slowing can affect how the pill is absorbed. If that's a reason for hesitation, it is worth flagging, it shapes which weight-loss medicine your prescriber might suggest instead. You can read more about who Mounjaro is and isn't suitable for as a starting point.

Step 2: Understand what Wegovy offers as the closest alternative

Wegovy is the brand name for semaglutide at weight-loss doses, made by Novo Nordisk. It works on a single receptor pathway (GLP-1) compared with Mounjaro's dual GIP and GLP-1 action. In practical terms, both medicines reduce appetite and slow gastric emptying; the mechanism differs, and in head-to-head trial evidence, Mounjaro produced greater average weight reduction, but Wegovy still delivered meaningful results: roughly 15% average body-weight reduction over 68 weeks at the 2.4mg maintenance dose in the STEP 1 trial, as published in the New England Journal of Medicine.

A higher 7.2mg dose was approved by the MHRA in 2026, with trial data suggesting around 20.7% average weight loss at that level, which narrows the gap with Mounjaro's results considerably. Wegovy is administered as a once-weekly subcutaneous injection, and the contraception interaction seen with Mounjaro is not supported by equivalent evidence for semaglutide, which matters for some patients. If you are weighing up your options and want to understand what BMI you need to have Mounjaro versus moving straight to an alternative, that can be a useful place to start before your consultation. You can explore weight-loss treatment options that our prescribers review.

Step 3: Consider the Wegovy tablet if injections are the sticking point

The MHRA approved oral semaglutide (Wegovy tablets) on 11 June 2026, making it the first oral GLP-1 medicine licensed for weight management in the UK. If the idea of a weekly injection is the main reason you are looking for something other than Mounjaro, this is worth knowing about.

The tablet is taken once daily, on an empty stomach first thing in the morning, with a small amount of plain water, waiting at least 30 minutes before eating, drinking anything else, or taking other oral medicines. No refrigeration is needed, which makes it considerably more travel-friendly than either injection. Trial data from the OASIS 4 study found an average weight reduction of around 13.6% over 64 weeks compared with placebo, rising to roughly 17% among participants who stayed fully adherent to treatment throughout. It is licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, alongside a reduced-calorie diet and increased activity, and our guidance on what BMI you need to get Mounjaro explains how those thresholds compare across treatments. The NHS medicines page for semaglutide carries patient-level information that is useful background reading.

Step 4: Know where orlistat fits, and where Ozempic does not

Orlistat is an older oral weight-loss medicine that works differently to GLP-1 and dual-agonist medicines: it blocks roughly a third of dietary fat from being absorbed in the gut. It does not suppress appetite in the same way, and the results in practice are more modest. It is available at lower doses without a prescription from a pharmacy, and at higher doses on prescription. For some people it remains a reasonable option, particularly if GLP-1 medicines are contraindicated. The weight-loss treatment overview on our site covers where orlistat sits alongside the newer options.

A common question is whether Ozempic or Rybelsus could be used instead of Mounjaro. They cannot, not for weight management. Both contain semaglutide, but they are licensed for type 2 diabetes, and prescribing them for weight loss in the UK would be off-label. Seeking them out as weight-loss medicines is not a safe alternative route. The MHRA's guidance on this is clear: GLP-1 medicines for weight loss and diabetes sets out which products are authorised for which indications. If you want to understand the full picture of your options and whether Mounjaro might still be suitable with the right support, our pages covering what BMI you need for Mounjaro and a fuller breakdown of BMI criteria for Mounjaro can help you arrive at your consultation better prepared. Our clinical team, including our lead prescriber, personally reviews every consultation, no algorithm involved. Speak to our prescribers through a free consultation whenever you are ready.